Beclomethasone dipropionate: A second chance for topical steroids as maintenance therapy in ileal Crohn's disease

Digestive and Liver Disease

Volumn 43, Issue 6, 2011, Pages 423-424

  Billioud, Vincent ^a   Peyrin Biroulet, Laurent ^a  

^a UNIVERSITY HOSPITAL OF NANCY   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BECLOMETASONE DIPROPIONATE; PREDNISONE;

COLITIS; CROHN DISEASE; DRUG EFFICACY; ENDOCRINE DISEASE; HUMAN; HYDROCORTISONE BLOOD LEVEL; ILEITIS; MAINTENANCE THERAPY; MULTICENTER STUDY (TOPIC); NOTE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENT DISEASE; SIDE EFFECT; ULCERATIVE COLITIS; UNSPECIFIED SIDE EFFECT;

ADMINISTRATION, TOPICAL; BECLOMETHASONE; CROHN DISEASE; GLUCOCORTICOIDS; HUMANS; RECURRENCE; REMISSION INDUCTION;

EID: 79955920594     PISSN: 15908658     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.dld.2011.03.008     Document Type: Note

References (12)

1. Peyrin-Biroulet L., Loftus E.V., Colombel J.F., et al. The natural history of adult Crohn's disease in population-based cohorts. Am J Gastroenterol 2009, 105:289-297.
2. Sandborn W.J., Lofberg R., Feagan B.G., et al. Budesonide for maintenance of remission in patients with Crohn's disease in medically induced remission: a predetermined pooled analysis of four randomized, double-blind, placebo-controlled trials. Am J Gastroenterol 2005, 100:1780-1787.
3. Dignass A., Van Assche G., Lindsay J.O., et al. The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: current management. J Crohn's Colitis 2010, 4:28-62.
4. Danese S., Angelucci E., Marconi S., et al. Oral beclomethasone: a review of its use in inflammatory bowel disease. Mini Rev Med Chem 2008, 8:1459-1463.
5. Biancone L., Gionchetti P., Blanco Gdel V., et al. Beclomethasone dipropionate versus mesalazine in distal ulcerative colitis: a multicenter, randomized, double-blind study. Dig Liver Dis 2007, 39:329-337.
6. Papi C., Aratari A., Moretti A., et al. Oral beclomethasone dipropionate as an alternative to systemic steroids in mild to moderate ulcerative colitis not responding to aminosalicylates. Dig Dis Sci 2002, 55:2002-2007.
7. Astegiano M., Pagano N., Sapone N., et al. Efficacy and safety of oral beclomethasone dipropionate for ileal or ileal-right colon Crohn's disease of mild-to-moderate activity or in remission: retrospective study. Biomed Pharmacother 2007, 61:370-376.
8. Prantera C., Rizzi M., Cottone M., et al. Beclomethasone dipropionate in Crohn's ileitis: a randomised, double-blind trial. Dig Liver Dis 2011, 43:459-464.
9. Tursi A., Giorgetti G.M., Brandimarte G., et al. Beclomethasone dipropionate for the treatment of mild-to-moderate Crohn's disease: an open-label, budesonide-controlled, randomized study. Med Sci Monit 2006, 12:PI29-PI32.
10. Lichtenstein G.R., Bengtsson B., Hapten-White L., et al. Oral budesonide for maintenance of remission of Crohn's disease: a pooled safety analysis. Aliment Pharmacol Ther 2009, 29:643-653.
11. Pineton de Chambrun G., Peyrin-Biroulet L., Lemann M., et al. Clinical implications of mucosal healing for the management of IBD. Nat Rev Gastroenterol Hepatol 2009, 7:15-29.
12. Mantzaris G.J., Christidou A., Sfakianakis M., et al. Azathioprine is superior to budesonide in achieving and maintaining mucosal healing and histologic remission in steroid-dependent Crohn's disease. Inflamm Bowel Dis 2009, 15:375-382.